PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.56%
Growth of 4.56% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
5.02%
Cost growth of 5.02% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
2.69%
Growth of 2.69% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
-1.79%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
265.94%
Other expenses change of 265.94% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
3.31%
Operating expenses change of 3.31% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
4.75%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 2.37%. Jim Chanos would check for waste.
-6.25%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
16.01%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos would check for overinvestment.
5.94%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
1.32%
Margin change of 1.32% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
0.67%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-3.72%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
86.77%
Other expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 7.03%. Jim Chanos would check for issues.
5.98%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
1.36%
Margin change of 1.36% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
27.47%
Tax expense change of 27.47% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
-4.69%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-8.85%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-4.70%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-4.70%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.